Literature DB >> 22066292

Immunogenicity and efficacy of Hoshino strain of mumps vaccine in Iran; two years study.

M Avijgan1, M Hafizi, M Moghni, S Kheiri, A Esteghamati, S Sarikhani.   

Abstract

This report describes the immunogenicity and efficacy and long term immunity of Hoshino strain of Mumps (included in MMR Vaccine) in shahr-e-kord, Islamic Republic of Iran (I.R.Iran). A total of 338 Children aged 3-18 years were tested for Mumps IgG using enzyme-linked immunosorbent assay (ELISA). The proportion of susceptible, mumps IgG negative, children was 19.8% (67 subjects). Of the 67 susceptible children, 36 received the MMR vaccination and successfully completed the study. Blood was collected by venipuncture 3, 12, and 24 months after vaccination and serum samples were tested by ELISA for detection of Mumps IgM and IgG. The overall seroconversion rate was 86.1%, 77.7% and 75% at 3, 12, and 24 months after vaccination respectively.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22066292

Source DB:  PubMed          Journal:  East Afr J Public Health        ISSN: 0856-8960


  2 in total

1.  Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.

Authors:  Ashwani Sood; Monjori Mitra; Himanshu Arvind Joshi; Uma Siddhartha Nayak; Prashanth Siddaiah; T Ramesh Babu; Samarendra Mahapatro; Jayesh Sanmukhani; Gaurav Gupta; Ravindra Mittal; Reinhard Glueck
Journal:  Hum Vaccin Immunother       Date:  2017-03-31       Impact factor: 3.452

2.  Three cases of mumps virus and enterovirus coinfection in children with enteroviral meningitis.

Authors:  Mojtaba Rasti; Manoochehr Makvandi; Niloofar Neisi; Azarakhsh Azaran; Nasrin Rastegarvand; Davod Khalafkhany; Emad Jahangirnezhad; Ali Teimoori; Maryam Hadian; Abdolnabi Shabani; Ahmad Shamsizadeh; Roya Nikfar; Mehran Varnaseri
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.